Drug utilization analysis of osteoporosis medications in seven European electronic health databases. Tan, E. H., Robinson, D. E., Jödicke, A. M., Mosseveld, M., Bødkergaard, K., Reyes, C., Moayyeri, A., Voss, A., Marconi, E., Lapi, F., Reinold, J., Verhamme, K. M. C., Pedersen, L., Braitmaier, M., de Wilde, M., Ruiz, M. F., Aragón, M., Bosco-Levy, P., Lassalle, R., Prieto-Alhambra, D., & Sanchez-Santos, M. T. Osteoporos Int, 34(10):1771-1781, 2023. 1433-2965 Tan, Eng Hooi Robinson, Danielle E Jödicke, Annika M Mosseveld, Mees Bødkergaard, Katrine Reyes, Carlen Moayyeri, Alireza Voss, Annemarie Marconi, Ettore Lapi, Francesco Reinold, Jonas Verhamme, Katia M C Pedersen, Lars Braitmaier, Malte de Wilde, Marcel Ruiz, Marc Far Aragón, María Bosco-Levy, Pauline Lassalle, Regis Prieto-Alhambra, Daniel Orcid: 0000-0002-3950-6346 Sanchez-Santos, Maria T Journal Article England 2023/07/12 Osteoporos Int. 2023 Oct;34(10):1771-1781. doi: 10.1007/s00198-023-06837-0. Epub 2023 Jul 12.abstract bibtex We studied the characteristics of patients prescribed osteoporosis medication and patterns of use in European databases. Patients were mostly female, older, had hypertension. There was suboptimal persistence particularly for oral medications. Our findings would be useful to healthcare providers to focus their resources on improving persistence to specific osteoporosis treatments. PURPOSE: To characterise the patients prescribed osteoporosis therapy and describe the drug utilization patterns. METHODS: We investigated the treatment patterns of bisphosphonates, denosumab, teriparatide, and selective estrogen receptor modulators (SERMs) in seven European databases in the United Kingdom, Italy, the Netherlands, Denmark, Spain, and Germany. In this cohort study, we included adults aged ≥ 18 years, with ≥ 1 year of registration in the respective databases, who were new users of the osteoporosis medications. The study period was between 01 January 2018 to 31 January 2022. RESULTS: Overall, patients were most commonly initiated on alendronate. Persistence decreased over time across all medications and databases, ranging from 52-73% at 6 months to 29-53% at 12 months for alendronate. For other oral bisphosphonates, the proportion of persistent users was 50-66% at 6 months and decreased to 30-44% at 12 months. For SERMs, the proportion of persistent users at 6 months was 40-73% and decreased to 25-59% at 12 months. For parenteral treatment groups, the proportions of persistence with denosumab were 50-85% (6 month), 30-63% (12 month) and with teriparatide 40-75% (6 month) decreasing to 21-54% (12 month). Switching occurred most frequently in the alendronate group (2.8-5.8%) and in the teriparatide group (7.1-14%). Switching typically occurred in the first 6 months and decreased over time. Patients in the alendronate group most often switched to other oral or intravenous bisphosphonates and denosumab. CONCLUSION: Our results show suboptimal persistence to medications that varied across different databases and treatment switching was relatively rare.
@article{RN432,
author = {Tan, E. H. and Robinson, D. E. and Jödicke, A. M. and Mosseveld, M. and Bødkergaard, K. and Reyes, C. and Moayyeri, A. and Voss, A. and Marconi, E. and Lapi, F. and Reinold, J. and Verhamme, K. M. C. and Pedersen, L. and Braitmaier, M. and de Wilde, M. and Ruiz, M. F. and Aragón, M. and Bosco-Levy, P. and Lassalle, R. and Prieto-Alhambra, D. and Sanchez-Santos, M. T.},
title = {Drug utilization analysis of osteoporosis medications in seven European electronic health databases},
journal = {Osteoporos Int},
volume = {34},
number = {10},
pages = {1771-1781},
note = {1433-2965 Tan, Eng Hooi Robinson, Danielle E Jödicke, Annika M Mosseveld, Mees Bødkergaard, Katrine Reyes, Carlen Moayyeri, Alireza Voss, Annemarie Marconi, Ettore Lapi, Francesco Reinold, Jonas Verhamme, Katia M C Pedersen, Lars Braitmaier, Malte de Wilde, Marcel Ruiz, Marc Far Aragón, María Bosco-Levy, Pauline Lassalle, Regis Prieto-Alhambra, Daniel Orcid: 0000-0002-3950-6346 Sanchez-Santos, Maria T Journal Article England 2023/07/12 Osteoporos Int. 2023 Oct;34(10):1771-1781. doi: 10.1007/s00198-023-06837-0. Epub 2023 Jul 12.},
abstract = {We studied the characteristics of patients prescribed osteoporosis medication and patterns of use in European databases. Patients were mostly female, older, had hypertension. There was suboptimal persistence particularly for oral medications. Our findings would be useful to healthcare providers to focus their resources on improving persistence to specific osteoporosis treatments. PURPOSE: To characterise the patients prescribed osteoporosis therapy and describe the drug utilization patterns. METHODS: We investigated the treatment patterns of bisphosphonates, denosumab, teriparatide, and selective estrogen receptor modulators (SERMs) in seven European databases in the United Kingdom, Italy, the Netherlands, Denmark, Spain, and Germany. In this cohort study, we included adults aged ≥ 18 years, with ≥ 1 year of registration in the respective databases, who were new users of the osteoporosis medications. The study period was between 01 January 2018 to 31 January 2022. RESULTS: Overall, patients were most commonly initiated on alendronate. Persistence decreased over time across all medications and databases, ranging from 52-73% at 6 months to 29-53% at 12 months for alendronate. For other oral bisphosphonates, the proportion of persistent users was 50-66% at 6 months and decreased to 30-44% at 12 months. For SERMs, the proportion of persistent users at 6 months was 40-73% and decreased to 25-59% at 12 months. For parenteral treatment groups, the proportions of persistence with denosumab were 50-85% (6 month), 30-63% (12 month) and with teriparatide 40-75% (6 month) decreasing to 21-54% (12 month). Switching occurred most frequently in the alendronate group (2.8-5.8%) and in the teriparatide group (7.1-14%). Switching typically occurred in the first 6 months and decreased over time. Patients in the alendronate group most often switched to other oral or intravenous bisphosphonates and denosumab. CONCLUSION: Our results show suboptimal persistence to medications that varied across different databases and treatment switching was relatively rare.},
keywords = {Adult
Humans
Female
Male
Alendronate/therapeutic use
*Bone Density Conservation Agents/therapeutic use
Teriparatide/therapeutic use
Denosumab/therapeutic use
Cohort Studies
Selective Estrogen Receptor Modulators
*Osteoporosis/drug therapy
Diphosphonates/therapeutic use
Drug Utilization
Electronics
*Osteoporosis, Postmenopausal/drug therapy
Anabolic drug
Anti-resorptive drug
Osteoporosis
Persistence
Switching ,
ISSN = 0937-941X (Print) 0937-941x ,
DOI = 10.1007/s00198-023-06837-0},
year = {2023},
type = {Journal Article}
}
Downloads: 0
{"_id":"qnwWy8czrb5qobsFh","bibbaseid":"tan-robinson-jdicke-mosseveld-bdkergaard-reyes-moayyeri-voss-etal-drugutilizationanalysisofosteoporosismedicationsinseveneuropeanelectronichealthdatabases-2023","author_short":["Tan, E. H.","Robinson, D. E.","Jödicke, A. M.","Mosseveld, M.","Bødkergaard, K.","Reyes, C.","Moayyeri, A.","Voss, A.","Marconi, E.","Lapi, F.","Reinold, J.","Verhamme, K. M. C.","Pedersen, L.","Braitmaier, M.","de Wilde, M.","Ruiz, M. F.","Aragón, M.","Bosco-Levy, P.","Lassalle, R.","Prieto-Alhambra, D.","Sanchez-Santos, M. T."],"bibdata":{"bibtype":"article","type":"Journal Article","author":[{"propositions":[],"lastnames":["Tan"],"firstnames":["E.","H."],"suffixes":[]},{"propositions":[],"lastnames":["Robinson"],"firstnames":["D.","E."],"suffixes":[]},{"propositions":[],"lastnames":["Jödicke"],"firstnames":["A.","M."],"suffixes":[]},{"propositions":[],"lastnames":["Mosseveld"],"firstnames":["M."],"suffixes":[]},{"propositions":[],"lastnames":["Bødkergaard"],"firstnames":["K."],"suffixes":[]},{"propositions":[],"lastnames":["Reyes"],"firstnames":["C."],"suffixes":[]},{"propositions":[],"lastnames":["Moayyeri"],"firstnames":["A."],"suffixes":[]},{"propositions":[],"lastnames":["Voss"],"firstnames":["A."],"suffixes":[]},{"propositions":[],"lastnames":["Marconi"],"firstnames":["E."],"suffixes":[]},{"propositions":[],"lastnames":["Lapi"],"firstnames":["F."],"suffixes":[]},{"propositions":[],"lastnames":["Reinold"],"firstnames":["J."],"suffixes":[]},{"propositions":[],"lastnames":["Verhamme"],"firstnames":["K.","M.","C."],"suffixes":[]},{"propositions":[],"lastnames":["Pedersen"],"firstnames":["L."],"suffixes":[]},{"propositions":[],"lastnames":["Braitmaier"],"firstnames":["M."],"suffixes":[]},{"propositions":["de"],"lastnames":["Wilde"],"firstnames":["M."],"suffixes":[]},{"propositions":[],"lastnames":["Ruiz"],"firstnames":["M.","F."],"suffixes":[]},{"propositions":[],"lastnames":["Aragón"],"firstnames":["M."],"suffixes":[]},{"propositions":[],"lastnames":["Bosco-Levy"],"firstnames":["P."],"suffixes":[]},{"propositions":[],"lastnames":["Lassalle"],"firstnames":["R."],"suffixes":[]},{"propositions":[],"lastnames":["Prieto-Alhambra"],"firstnames":["D."],"suffixes":[]},{"propositions":[],"lastnames":["Sanchez-Santos"],"firstnames":["M.","T."],"suffixes":[]}],"title":"Drug utilization analysis of osteoporosis medications in seven European electronic health databases","journal":"Osteoporos Int","volume":"34","number":"10","pages":"1771-1781","note":"1433-2965 Tan, Eng Hooi Robinson, Danielle E Jödicke, Annika M Mosseveld, Mees Bødkergaard, Katrine Reyes, Carlen Moayyeri, Alireza Voss, Annemarie Marconi, Ettore Lapi, Francesco Reinold, Jonas Verhamme, Katia M C Pedersen, Lars Braitmaier, Malte de Wilde, Marcel Ruiz, Marc Far Aragón, María Bosco-Levy, Pauline Lassalle, Regis Prieto-Alhambra, Daniel Orcid: 0000-0002-3950-6346 Sanchez-Santos, Maria T Journal Article England 2023/07/12 Osteoporos Int. 2023 Oct;34(10):1771-1781. doi: 10.1007/s00198-023-06837-0. Epub 2023 Jul 12.","abstract":"We studied the characteristics of patients prescribed osteoporosis medication and patterns of use in European databases. Patients were mostly female, older, had hypertension. There was suboptimal persistence particularly for oral medications. Our findings would be useful to healthcare providers to focus their resources on improving persistence to specific osteoporosis treatments. PURPOSE: To characterise the patients prescribed osteoporosis therapy and describe the drug utilization patterns. METHODS: We investigated the treatment patterns of bisphosphonates, denosumab, teriparatide, and selective estrogen receptor modulators (SERMs) in seven European databases in the United Kingdom, Italy, the Netherlands, Denmark, Spain, and Germany. In this cohort study, we included adults aged ≥ 18 years, with ≥ 1 year of registration in the respective databases, who were new users of the osteoporosis medications. The study period was between 01 January 2018 to 31 January 2022. RESULTS: Overall, patients were most commonly initiated on alendronate. Persistence decreased over time across all medications and databases, ranging from 52-73% at 6 months to 29-53% at 12 months for alendronate. For other oral bisphosphonates, the proportion of persistent users was 50-66% at 6 months and decreased to 30-44% at 12 months. For SERMs, the proportion of persistent users at 6 months was 40-73% and decreased to 25-59% at 12 months. For parenteral treatment groups, the proportions of persistence with denosumab were 50-85% (6 month), 30-63% (12 month) and with teriparatide 40-75% (6 month) decreasing to 21-54% (12 month). Switching occurred most frequently in the alendronate group (2.8-5.8%) and in the teriparatide group (7.1-14%). Switching typically occurred in the first 6 months and decreased over time. Patients in the alendronate group most often switched to other oral or intravenous bisphosphonates and denosumab. CONCLUSION: Our results show suboptimal persistence to medications that varied across different databases and treatment switching was relatively rare.","keywords":"Adult Humans Female Male Alendronate/therapeutic use *Bone Density Conservation Agents/therapeutic use Teriparatide/therapeutic use Denosumab/therapeutic use Cohort Studies Selective Estrogen Receptor Modulators *Osteoporosis/drug therapy Diphosphonates/therapeutic use Drug Utilization Electronics *Osteoporosis, Postmenopausal/drug therapy Anabolic drug Anti-resorptive drug Osteoporosis Persistence Switching , ISSN = 0937-941X (Print) 0937-941x , DOI = 10.1007/s00198-023-06837-0","year":"2023","bibtex":"@article{RN432,\r\n author = {Tan, E. H. and Robinson, D. E. and Jödicke, A. M. and Mosseveld, M. and Bødkergaard, K. and Reyes, C. and Moayyeri, A. and Voss, A. and Marconi, E. and Lapi, F. and Reinold, J. and Verhamme, K. M. C. and Pedersen, L. and Braitmaier, M. and de Wilde, M. and Ruiz, M. F. and Aragón, M. and Bosco-Levy, P. and Lassalle, R. and Prieto-Alhambra, D. and Sanchez-Santos, M. T.},\r\n title = {Drug utilization analysis of osteoporosis medications in seven European electronic health databases},\r\n journal = {Osteoporos Int},\r\n volume = {34},\r\n number = {10},\r\n pages = {1771-1781},\r\n note = {1433-2965 Tan, Eng Hooi Robinson, Danielle E Jödicke, Annika M Mosseveld, Mees Bødkergaard, Katrine Reyes, Carlen Moayyeri, Alireza Voss, Annemarie Marconi, Ettore Lapi, Francesco Reinold, Jonas Verhamme, Katia M C Pedersen, Lars Braitmaier, Malte de Wilde, Marcel Ruiz, Marc Far Aragón, María Bosco-Levy, Pauline Lassalle, Regis Prieto-Alhambra, Daniel Orcid: 0000-0002-3950-6346 Sanchez-Santos, Maria T Journal Article England 2023/07/12 Osteoporos Int. 2023 Oct;34(10):1771-1781. doi: 10.1007/s00198-023-06837-0. Epub 2023 Jul 12.},\r\n abstract = {We studied the characteristics of patients prescribed osteoporosis medication and patterns of use in European databases. Patients were mostly female, older, had hypertension. There was suboptimal persistence particularly for oral medications. Our findings would be useful to healthcare providers to focus their resources on improving persistence to specific osteoporosis treatments. PURPOSE: To characterise the patients prescribed osteoporosis therapy and describe the drug utilization patterns. METHODS: We investigated the treatment patterns of bisphosphonates, denosumab, teriparatide, and selective estrogen receptor modulators (SERMs) in seven European databases in the United Kingdom, Italy, the Netherlands, Denmark, Spain, and Germany. In this cohort study, we included adults aged ≥ 18 years, with ≥ 1 year of registration in the respective databases, who were new users of the osteoporosis medications. The study period was between 01 January 2018 to 31 January 2022. RESULTS: Overall, patients were most commonly initiated on alendronate. Persistence decreased over time across all medications and databases, ranging from 52-73% at 6 months to 29-53% at 12 months for alendronate. For other oral bisphosphonates, the proportion of persistent users was 50-66% at 6 months and decreased to 30-44% at 12 months. For SERMs, the proportion of persistent users at 6 months was 40-73% and decreased to 25-59% at 12 months. For parenteral treatment groups, the proportions of persistence with denosumab were 50-85% (6 month), 30-63% (12 month) and with teriparatide 40-75% (6 month) decreasing to 21-54% (12 month). Switching occurred most frequently in the alendronate group (2.8-5.8%) and in the teriparatide group (7.1-14%). Switching typically occurred in the first 6 months and decreased over time. Patients in the alendronate group most often switched to other oral or intravenous bisphosphonates and denosumab. CONCLUSION: Our results show suboptimal persistence to medications that varied across different databases and treatment switching was relatively rare.},\r\n keywords = {Adult\r\nHumans\r\nFemale\r\nMale\r\nAlendronate/therapeutic use\r\n*Bone Density Conservation Agents/therapeutic use\r\nTeriparatide/therapeutic use\r\nDenosumab/therapeutic use\r\nCohort Studies\r\nSelective Estrogen Receptor Modulators\r\n*Osteoporosis/drug therapy\r\nDiphosphonates/therapeutic use\r\nDrug Utilization\r\nElectronics\r\n*Osteoporosis, Postmenopausal/drug therapy\r\nAnabolic drug\r\nAnti-resorptive drug\r\nOsteoporosis\r\nPersistence\r\nSwitching ,\r\nISSN = 0937-941X (Print) 0937-941x ,\r\nDOI = 10.1007/s00198-023-06837-0},\r\n year = {2023},\r\n type = {Journal Article}\r\n}\r\n\r\n","author_short":["Tan, E. H.","Robinson, D. E.","Jödicke, A. M.","Mosseveld, M.","Bødkergaard, K.","Reyes, C.","Moayyeri, A.","Voss, A.","Marconi, E.","Lapi, F.","Reinold, J.","Verhamme, K. M. C.","Pedersen, L.","Braitmaier, M.","de Wilde, M.","Ruiz, M. F.","Aragón, M.","Bosco-Levy, P.","Lassalle, R.","Prieto-Alhambra, D.","Sanchez-Santos, M. T."],"key":"RN432","id":"RN432","bibbaseid":"tan-robinson-jdicke-mosseveld-bdkergaard-reyes-moayyeri-voss-etal-drugutilizationanalysisofosteoporosismedicationsinseveneuropeanelectronichealthdatabases-2023","role":"author","urls":{},"keyword":["Adult Humans Female Male Alendronate/therapeutic use *Bone Density Conservation Agents/therapeutic use Teriparatide/therapeutic use Denosumab/therapeutic use Cohort Studies Selective Estrogen Receptor Modulators *Osteoporosis/drug therapy Diphosphonates/therapeutic use Drug Utilization Electronics *Osteoporosis","Postmenopausal/drug therapy Anabolic drug Anti-resorptive drug Osteoporosis Persistence Switching","ISSN = 0937-941X (Print) 0937-941x","DOI = 10.1007/s00198-023-06837-0"],"metadata":{"authorlinks":{}},"html":""},"bibtype":"article","biburl":"https://bibbase.org/network/files/qwipow2DJsAxqNp83","dataSources":["PJSqX8FMpCPRdw3CQ","qLDnCcKM9omXNrRY8","TB9sD3avjy7bNxfgS","vDmJPYmHEKAT3tMNL","PcZMFHooKwpboi2he","jZMXEeHTfokmisJDv"],"keywords":["adult humans female male alendronate/therapeutic use *bone density conservation agents/therapeutic use teriparatide/therapeutic use denosumab/therapeutic use cohort studies selective estrogen receptor modulators *osteoporosis/drug therapy diphosphonates/therapeutic use drug utilization electronics *osteoporosis","postmenopausal/drug therapy anabolic drug anti-resorptive drug osteoporosis persistence switching","issn = 0937-941x (print) 0937-941x","doi = 10.1007/s00198-023-06837-0"],"search_terms":["drug","utilization","analysis","osteoporosis","medications","seven","european","electronic","health","databases","tan","robinson","jödicke","mosseveld","bødkergaard","reyes","moayyeri","voss","marconi","lapi","reinold","verhamme","pedersen","braitmaier","de wilde","ruiz","aragón","bosco-levy","lassalle","prieto-alhambra","sanchez-santos"],"title":"Drug utilization analysis of osteoporosis medications in seven European electronic health databases","year":2023}